How could Johnson & Johnson's strong drug sales affect Eli Lilly and Company?
J&J's strong drug sales could intensify competition for Eli Lilly in key markets. Johnson & Johnson's innovative medicine segment showed robust growth, driven by products like Darzalex, which posted sales of $4.2 billion, 15.4% higher than the year-ago period, and Tremfya, which generated $2.4 billion, up 68.3% from the prior-year quarter. This strong performance, coupled with the launch of new medicines such as ICOTYDE and Imaavy, suggests sustained growth in key therapeutic areas. Given that Johnson & Johnson and Eli Lilly and Company are engaged in direct, high-stakes market competition across various segments, J&J's success could intensify competitive pressure on Eli Lilly in those shared markets.
- Effect
- Mild negative
- How direct
- Brind's reasoning
- When
- Within weeks
- The story
- No new developments lately
How it reaches Eli Lilly and Company
-
Johnson & Johnson reported third-quarter revenue of $25.4 billion, which was 5.9% higher than the previous year. The innovative medicine segment generated $16.8 billion, up 7.7% year over year. While Darzalex sales increased 15.4% and Tremfya sales increased 68.3%, other key medicines faced declining sales due to competition.
The full event1independent outlet -
The reports confirm that Johnson & Johnson and Eli Lilly and Company are engaged in direct, high-stakes market competition across various therapeutic and growth segments. J&J's demonstrated ability to drive strong sales and launch new medicines could increase the competitive intensity for Eli Lilly in these shared areas.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
American pharmaceutical company
Everything about Eli Lilly and Company
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Johnson & Johnson's innovative medicine segment recorded sales of $16.8 billion, up 7.7% year over year.fool.com
- Darzalex posted sales of $4.2 billion, 15.4% higher than the year-ago period.fool.com
- Tremfya generated $2.4 billion in sales, up 68.3% from the prior-year quarter.fool.com
- Johnson & Johnson and Eli Lilly and Company are engaged in direct, high-stakes market competition across various therapeutic and growth segments.fool.com
Why it matters
For Eli Lilly and Company, the pharmaceutical market is defined by intense rivalry with giants like Johnson & Johnson. J&J's reported success, driven by high-growth products and new launches, signals continued strength in key therapeutic areas. This puts pressure on Eli Lilly to maintain or accelerate its own growth trajectory and market share in these competitive segments.
This dynamic is typical of the large-scale pharmaceutical industry, where market dominance is often determined by the success of flagship drugs and the speed of new product approvals. The ability of J&J to sustain growth and increase its guidance for the full fiscal year 2026 highlights the competitive environment in which Eli Lilly operates.
What we don't know yet
- Which specific therapeutic segments are the two companies competing in most intensely?
- How will Eli Lilly and Company respond to the sustained growth shown by Johnson & Johnson's innovative medicine segment?
What would change this answer
— Other considerations
Beyond this explainer
Questions worth asking
Ideas the web ties closely to this story that the explainer doesn't mention. These are prompts for your own research: Brind hasn't answered them.
-
About Remicade
If Remicade is declining, does this suggest that Johnson & Johnson's overall strength is concentrated in its newer products like Darzalex and Tremfya?
Related on BrindJohnson & Johnson reports mixed sales performance for several key drugs, with Imbruvica and Remicade declining while Darzalex and Tremfya show strong sales.
Explore connected ideas
Each opens in Related concepts: what the web connects to it, with Brind's news on it.
The ideas come from how millions of web pages place them near each other. The questions are Brind's AI reasoning, written only from this explainer and Brind's own reporting.
Who else could feel it
Other possible ripples from the same event.
Reporting
- fool.comSaturday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.